Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease
Launched by NHS GREATER GLASGOW AND CLYDE · Jun 19, 2008
Trial Information
Current as of July 21, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • symptomatic NYHA II or III chronic heart failure
- • left ventricular systolic dysfunction
- • moderate or severe chronic obstructive pulmonary disease
- • with or without significant reversibility
- Exclusion Criteria:
- • beta-blocker contraindications
- • non-dihydropyridine (diltiazem / verapamil) calcium channel blockers
- • recent coronary percutaneous intervention or coronary artery bypass graft surgery
- • haemodynamically significant valvular disease or hypertrophic cardiomyopathy.
- • active myocarditis or pericarditis.
- • recent cerebrovascular accident or transient ischaemic attack
- • serious concurrent systemic disease, such as malignancy, resulting in likely reduced life expectancy
- • pregnancy, childbearing potential with inadequate contraception, breast feeding
About Nhs Greater Glasgow And Clyde
NHS Greater Glasgow and Clyde (NHS GG&C) is one of the largest health organizations in the UK, dedicated to delivering high-quality healthcare services to a diverse population. As a clinical trial sponsor, NHS GG&C plays a pivotal role in advancing medical research and improving patient outcomes through innovative clinical studies. The organization is committed to upholding rigorous ethical standards and regulatory compliance, ensuring that all trials are conducted with the utmost care for participant safety and scientific integrity. With a focus on collaboration, NHS GG&C partners with academic institutions, healthcare professionals, and industry stakeholders to foster an environment conducive to groundbreaking research and the development of new therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glasgow, Scotland, United Kingdom
Patients applied
Trial Officials
Nathaniel M Hawkins, MBChB
Principal Investigator
NHS Greater Glasgow and Clyde
Francis G Dunn, MBChB MD
Study Chair
NHS Greater Glasgow and Clyde
Roger Carter, BSc MSc PHD
Study Director
NHS Greater Glasgow and Clyde
George W Chalmers, MBChB MD
Study Director
NHS Greater Glasgow and Clyde
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials